Helena Danielson, Prof.
Chief Scientific Officer
Helena Danielson co-founded Beactica in 2006 and is Chief Scientific Officer. She is a specialist in enzyme-based drug discovery and has adapted biosensor technology for detailed studies of enzyme-inhibitor interactions. She has profound experience of the commercial drug discovery process through more than 15 years of collaborative research with industrial partners.
At the Karolinska Institute she initiated a research project on HIV protease as a drug target for AIDS. In 1987 this work lead to a collaboration with Medivir AB that has been ongoing since. Her longstanding work with Biacore AB has resulted in the development of new biosensor products of wide use in the discovery industry. She is Professor of Biochemistry at Uppsala University since 2002.
